Építés alatt – nem éles oldal
Belépés
Leállítva2. fázis

Pediatric Study of GVHD Ppx w/o Calcineurin Inhibitors After Day60 Post First Allo HSCT for Hematological Malignancies.

A legfontosabb adatok

Ki végzi
St. Jude Children's Research Hospital
Hol
Memphis (Egyesült Államok)A helyszín megnézése
Azonosító
Állapot
Leállítva
Fázis
2. fázis
Résztvevők
3 fő vett részt
Kezdés
2023. márc. 14.
Befejezés
2024. máj. 8.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • Ruxolitinib
  • Mesna
  • Anti-thymocyte globulin (ATG)
  • Cyclosporine
  • Cyclophosphamide
  • Fludarabine
  • Methotrexate
  • Total Body Irradiation (radiation treatment)
  • Bone marrow infusion
  • Busulfan
  • Thiotepa
A regiszteradat frissítve
2025. október 2.
Miért állt le
Principal Investigator left institution

Ki vehet részt

Életkor
12 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 20 feltétel megnézéseKevesebb

Ki vehet részt

  • Diagnosis:
  • Patients with high risk acute lymphoblastic leukemia in first remission. Examples include, but are not limited to, patients with certain leukemic cell cytogenetic findings (e.g. t(9;22) or t(4;11)); delayed response to induction chemotherapy; re-emergence of leukemic blasts by MRD (at any level) in patients previously MRD negative; persistently detectable MRD at lower levels; early T-cell precursor (ETP) ALL
  • Patients with acute lymphoblastic leukemia beyond first remission
  • Patients with Hodgkin's disease beyond first remission or with refractory disease
  • Patients with chronic myelogenous leukemia
  • Patients with primary or secondary myelodysplastic syndrome
  • Patients with Non-Hodgkin's lymphoma beyond first remission or with refractory disease
  • Patients with de novo acute myeloid leukemia in or beyond first remission or with relapsed or refractory disease, or myeloid sarcoma (extra-medullary AML)
  • Patients with secondary acute myeloid leukemia
  • NK cell lymphoblastic leukemia in any CR
  • Biphenotypic, bilineage, or undifferentiated leukemia
  • Juvenile Myelomonocytic Leukemia (JMML)
  • All patients with prior evidence of CNS leukemia must be treated and be in CNS CR; Patients must have a related or unrelated donor matched at 12 of 12 HLA alleles; Patient must have a Karnofsky/Lansky score of 70 or higher; Patients must be 12 years of age or older; Patients must have a shortening fraction >26% or left ventricular ejection fraction >40%; Patients must have bilirubin less than or equal to 2.5 mg/dL and alanine aminotransferase (ALT) less than or equal to 5 times the upper limit of normal; Patients must have creatinine clearance, or a glomerular filtration rate (GFR), greater than 70 mL/min/1.73m2; Patients must be free of severe infection that upon determination of principal investigator precludes BMT; Patients must have FVC >50% predicted OR, if unable to perform pulmonary function testing, must maintain pulse oximetry oxygen saturation >92% on room air; Female patients of childbearing age must have a negative pregnancy test

Ki nem vehet részt

  • Patients who have undergone prior HCT
  • Patients who are HIV positive
  • Patients positive for Hepatitis B surface antigen (HBsAg)
  • Patients positive for Hepatitis C
  • Patients with latent tuberculosis with positive TB IFN gamma release assay
  • Patients who have a peripheral blood stem cell graft source
  • Patients who have a non-permissive mismatch at the DPB1 allele

Helyszínek itt: Egyesült Államok

  • St. Jude Children's Research HospitalMemphis, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

The participants are being asked to take part in this clinical trial because the participant have a lymphoid or myeloid based cancer diagnosis that requires a bone marrow transplant.

A teljes eredeti leírásKevesebb

Primary Objectives

To estimate the incidence of severe acute GVHD (saGVHD) using a prophylaxis regimen with no calcineurin inhibitors after day +60 post first allogeneic Human Leukocyte antigen (HLA)-matched sibling or unrelated donor HCT for hematological malignancies.

Secondary objective

Determine the cumulative incidence of relapse, NRM, chronic GVHD, and OS in study participants at one year post-transplant.

Exploratory objectives

* To evaluate the pharmacokinetic/pharmacodynamic (PK/PD) profiles of ruxolitinib, fludarabine, and rATG. * To assess immune reconstitution in study participants within the first year post-HCT.

A vizsgálat csoportja

  • Transplant PatientsA vizsgált kezelés

    Kezelés: Ruxolitinib, Mesna, Anti-thymocyte globulin (ATG), Cyclosporine, Cyclophosphamide, Fludarabine, Methotrexate, Total Body Irradiation (radiation treatment), Bone marrow infusion, Busulfan és Thiotepa

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Phase II Pediatric Study of a Graft-VS.-Host Disease (GVHD) Prophylaxis Regimen With no Calcineurin Inhibitors After Day +60 Post First Allogeneic Hematopoietic Cell Transplant for Hematological Malignancies
A regiszteradat frissítve
2025. október 2.